A Phase I, Single Arm, Multiple Dose, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
At a glance
- Drugs KN 035 (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors 3D Medicines
- 08 Jan 2018 Planned number of patients changed from 36 to 60.
- 08 Jan 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 07 Apr 2017 New trial record